Form 4 for ABBV AbbVie
Accepted 2023-02-21 00:00:00 ET · period of report 2023-02-16 · accession 0001415889-23-002942 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-21 | 2023-02-16 | ABBV | Reents Scott T | EVP, CFO | A - Grant | $0.00 | +28.6K | 27.0K | New | $0 |
| D | 2023-02-21 | 2023-02-16 | ABBV | Reents Scott T | EVP, CFO | A - Grant | $0.00 | +33.8K | 33.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2023-02-16 | A | A | 4,366 | $0.00 | 23,890 | D | — | — | (F2) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| 2 | Common | Common Stock, $0.01 par value | 2023-02-16 | A | A | 2,398 | $0.00 | 29,434 | D | — | — | (F4) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| 3 | Common | Common Stock, $0.01 par value | 2023-02-16 | A | A | 18,715 | $0.00 | 19,524 | D | — | — | (F1) Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| 4 | Common | Common Stock, $0.01 par value | 2023-02-16 | A | A | 3,146 | $0.00 | 27,036 | D | — | — | (F3) Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| 5 | Derivative | Option (Right to buy) | 2023-02-16 | A | A | 33,760 | $0.00 | 33,760 | D | $149.62 · 2024-02-16 to 2033-02-15 | 33,760 Common Stock | (F5) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,254 on February 16, 2024, 11,253 on February 16, 2025, and 11,253 on February 16, 2026. |